4 results about "Long acting insulin" patented technology

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fe fusion proteins for use in treating canine and feline diabetes. The insulin-Fe fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fe-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-dmg antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious com- bination of insulin polypeptide, peptide linkers, and species-specific Fe fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fe fusion proteins, polynucleotides encoding these insulin-Fe fusion proteins, and pharmaceutical formulations of exemplary insulin-Fe fusion proteins are provided, in addition to methods of use and preparation. 20 24 28 71 86 23 D ec 2 02 4 1 0 0 5 6 8 8 4 5 4 A B S T R A C T 2 0 2 4 2 8 7 1 8 6 2 3 D e c 2 0 2 4

The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U / mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

This invention relates to the field of cell culture technology, and more particularly to a culture medium additive for mesenchymal stem cells and its application. The culture medium additive of this invention, using water as a solvent, comprises the following components at the following concentrations: 0.5-1.5 mg / L rhTXNDC5 protein, 10-20 mg / L vascular endothelial cadherin 5, 10-20 mg / L vascular endothelial cadherin 11, 10-20 mg / L recombinant human long-acting insulin-like growth factor-1, 400-600 mg / L dextran, 200-400 mg / L riboflavin, 300-500 IU / L superoxide dismutase, 10-20 mg / L ethanolamine, and 1-3 mg / L progesterone. Adding this culture medium additive to serum-free culture medium can increase the yield of mesenchymal stem cells and accelerate the emergence time of umbilical cord mesenchymal stem cells.